FDA approves Ionis’ hereditary angioedema drug
Dawnzera is the third medicine cleared by U.S. regulators this year for the rare genetic condition. Ionis set its list price at $57,462 per dose.
Previous Post
CDC advisory panel member no longer trusts CDC
Next Post
Friends of Cancer Research and MMS partner to improve interpretation of cancer trial survival data
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago